Tenorio G, Zambrano SP

Language: Spanish
References: 14
Page: 20-28
PDF size: 114.42 Kb.

ABSTRACT

Introduction: Chloroquine is indicated frequently in rheumatic and dermatologic diseases as an anti-inflammatory and to protect the photosensibility reactions of the skin. One of the adverse effect of the chloroquine is that it is deposited in the retinal pigment. Objective: to determine the efficacy of the contrast sensitivity test (CST) in patients with chloroquine treatment, comparing dose per day. Methods: We reviewed 52 medical histories of patients under chloroquine treatment for more than one year, including with visual acuity (VA) of 20/40 or better because the CST works with this lines of VA. Results: From the 52 patients, studied 51 women, the diagnostic was of rheumatoid arthritis in 52%, eritematosus lupus in the 46% and the rest dermatitis solar. The VA were 20/20, 20/25,20/30 and 20/40. The CST was normal. The fundus eye was abnormal in 2 patients with lupus eritematosus, they had subfoveal pigment, with VA of 20/30 and were taking 300 mg and 450 mg of chloroquine daily. Conclusions: The CST did not demonstrate difference with normal spacial frequencies, maybe only the total dose is retino-toxic.

REFERENCES

1. Easterbrook M. Dose relationships in patients with early chloroquine retinopathy. J Rheumatol 1987; 13: 472-480.

2. David J, Browning MD. Hidroxychloroquine and chloroquine Retinopathy: Screening for drug toxicity. Am J Ophthalmol 2002; 6: 649-655.

3. Quiroz M, Jiménez S, Ochoa C, Morales C, Dalma W. En: Retina Diagnóstico y Tratamiento. 2a ed. México: Laboratorios Sophia, 2006; 229-230.

4. Easterbrook M. An ophthalmological view on the efficacy and safety of chloroquine versus hydroxychloroquine. J Rheumatol 1999; 26: 1866-1867.

5. Ferreras A, Pinilla I, Abecia E, Pajarin AB. Toxicidad retiniana secundaria a tratamiento con cloroquina. Arch Soc Esp Oftalmol 2007; 82: 103-108.

6. Vu L, Easterbrook M, Hovis JK. Detection of color vision defects in chloroquine retinopathy. Ophthalmology 1999; 106: 1799-1804.

7. Gouras P, Gunkel RD. The EOG in chloroquine and other retinopathies. Arch Ophthalmol 1963; 70: 91-101.

8. Henkind P, Carr RE, Siegel IM. Early chloroquine retinopathy: Clinical and functional findings. Arch Ophthalmol 1964; 71: 65-73.

9. Tenorio G, Hernández C, Robles B. La prueba de sensibilidad de contraste y el campo visual central en el diagnóstico de retinopatía por cloroquina. Rev Med Hosp Gen 1998; 61: 140-146.

10. Shroyer NF, Lewis RA, Pupski JR. Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: Is retinal toxicity by chlororoquine and hydroxychloroquine related to Stargardt disease? Am J Ophthalmol 2001; 131: 761-766.

11. Matsumura M, Onkuma M, Tsukahara I. Experimental chloroquine retinopathy. Ophthalmic Res 1986; 18: 172-180.

12. Wainer IW, Chen JC, Parenteau H, Abdullah S, Duchame J. Distribution of the enantiomers of hydroxychloroquine and its metabolites in ocular tissues of the rabbit after oral administration of racemic-hydroxychloroquine. Chiralty 1994; 6: 347-354.

13. Grierson DJ. Hydroxychloroquine and visual screening in a rheumatology outpatient clinic. Ann Rheumatol Dis 1997; 56: 188-190.

14. Neubauer AS, Samari-Kermani K, Schaller U, Welgi-Lübetaen U, Rudolph G, Berninger I. Detecting chloroquine retinopathy: Electro-oculogram versus color vision. Br J Ophthalmol 2003; 87: 902-908.